Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhuMAb VEGF · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| rhuMAb VEGF (Bevacizumab) | DRUG | - |
| rhuMAb VEGF (telbermin) | DRUG | - |
Inclusion Criteria: * Written informed consent * Women \>=18 years of age * Histologically confirmed carcinoma of the breast with metastatic disease that is currently progressing; in subjects who present with metastatic disease, cytologic confirmation is permissible * Prior administration of one or...
Top 20 of 92 competitors
rhuMAb VEGF is being studied for use in breast cancer and foot ulcers. In breast cancer, it is evaluated in combination with chemotherapy in patients with previously treated disease. In foot ulcers, it is studied as a topical treatment for chronic diabetic foot ulcers. The drug is currently in clinical development.
rhuMAb VEGF targets vascular endothelial growth factor (VEGF), a protein that promotes blood vessel growth. By binding to VEGF, the drug may inhibit angiogenesis, which is important in tumor growth and wound healing. This mechanism is relevant to its potential use in oncology and ulcer treatment.
rhuMAb VEGF is developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded over-the-counter under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in the studied indications.
rhuMAb VEGF is in Phase 3 clinical development for breast cancer. A Phase 3 trial has been completed, though the drug remains investigational and is not yet approved. A separate Phase 1 trial for foot ulcers has also been completed. The drug is still in clinical development.
rhuMAb VEGF has been studied in two completed trials. NCT00069446 was a Phase 1 study of topical recombinant human VEGF for chronic diabetic foot ulcers with 50 participants. NCT00109239 was a Phase 3 study of rhuMAb VEGF plus chemotherapy in previously treated breast cancer patients.
rhuMAb VEGF is also known as bevacizumab, as indicated in the Phase 3 breast cancer trial title. Bevacizumab is a monoclonal antibody that targets VEGF. The drug is being developed by Roche for oncology and wound healing indications.